UPB · ISSUER CIK 2022626
Upstream Bio, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 5 Upstream Bio, Inc. insiders reported $0.00 of open-market purchases and $28K of sales on SEC Form 4.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 5 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$28KInsider selling
−$28KNet open-market
Sep 17, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 202616:05 | Sep 16, 2026 | UPB | CFO and COO | S · Sell | $5.49 | −853 | 27,942 | -3% | −$5K | ||
| Sep 17, 202616:05 | Sep 16, 2026 | UPB | General Counsel | S · Sell | $5.49 | −485 | 15,563 | -3% | −$3K | ||
| Sep 17, 202616:05 | Sep 16, 2026 | UPB | Chief Medical Officer | S · Sell | $5.49 | −895 | 32,302 | -3% | −$5K | ||
| Sep 17, 202616:05 | Sep 16, 2026 | UPB | Chief Executive Officer, Director | S · Sell | $5.49 | −2,095 | 68,717 | -3% | −$12K | ||
| Sep 17, 202616:05 | Sep 16, 2026 | UPB | Chief Business Officer | S · Sell | $5.49 | −700 | 22,901 | -3% | −$4K |